The number of on-site inspections of medical device facilities performed by the US Food and Drug Administration between mid-July and mid-November fell by an eye-popping 93% from the same time frame last year. That’s forced the agency to consider creative techniques, including records requests and the use of video, for remotely evaluating manufacturer compliance during the COVID-19 pandemic.
The FDA told Medtech Insight it conducted a mere 35 domestic in-person inspections from 20 July – when the agency began inspecting again following a four-month break due to the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?